Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received acceptance for its drug application for SHR-A1811 (注射用瑞康曲妥珠单抗) from the National Medical Products Administration, which has been included in the priority review process [1] Group 1: Drug Application and Clinical Trials - The drug application is based on a randomized, open-label, positive-controlled, multi-center Phase III clinical trial [1] - The trial aims to evaluate the efficacy and safety of SHR-A1811 compared to standard treatment in HER2-positive advanced colorectal cancer patients who have failed previous treatments with oxaliplatin, fluorouracil, and irinotecan [1] - The study is led by Dr. Li Jin from Shanghai Gaobo Cancer Hospital and Professor Yuan Ying from the Second Affiliated Hospital of Zhejiang University School of Medicine, with participation from 40 centers nationwide [1] Group 2: Study Outcomes - The primary endpoint of the study is progression-free survival (PFS) assessed by an independent imaging review committee (IRC) according to RECIST v1.1 [1] - Results indicate that SHR-A1811 significantly extends PFS in HER2-positive advanced colorectal cancer patients compared to standard treatment, reducing the risk of disease progression or death [1] - Overall survival (OS) data shows a trend of benefit, although it is currently only observed [1]

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received a notice from the National Medical Products Administration (NMPA) regarding the acceptance of its drug application for injection of Rukang Trastuzumab, which is now included in the priority review process [1] Group 1 - The drug name is Rukang Trastuzumab for injection [1] - The dosage form is an injection [1] - The acceptance number for the application is CXSS2600018 [1] Group 2 - The application is currently in the listing phase [1] - The applicant for the drug is Suzhou Merdia Biopharmaceutical Co., Ltd., a subsidiary of the company [1] - The proposed indication is for the treatment of adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin, fluorouracil, and irinotecan [1]

本次新适应症申报是基于一项随机、开放、阳性药物对照、多中心设计的Ⅲ 期临床试验，该研究旨在 评估瑞康曲妥珠单抗(SHR-A1811)对比标准治疗方案在经奥沙利铂、氟尿嘧啶类和伊立替康治疗失败的 HER2阳性晚期结直肠癌受试者中的有效性和安全性，并探索该药物的免疫原性及药代动力学特征。本 研究由上海高博肿瘤医院李进院长和浙江大学医学院附属第二医院袁瑛教授共同担任主要研究者，全国 40家中心共同参与。主要终点为独立影像评审委员会(IRC)依据RECIST v1.1 评估的无进展生存期 (PFS)。研究结果显示，与标准治疗方案相比，瑞康曲妥珠单抗能显著延长HER2 阳性晚期结直肠癌患 者的PFS，降低疾病进展或死亡风险。总生存期(OS)数据目前观察到获益趋势。 智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称"公司")子公 司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(以下简称"国家药监局")下发的《受理通知 书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。 ...

Core Viewpoint - Zhuzhou Qianjin Pharmaceutical Co., Ltd. reported significant growth in core profit indicators for the fiscal year 2025, with a stable operating performance and positive responses to investor concerns regarding market value management, R&D pace, and new industrialization layout [1][2][3] Financial Performance - The company achieved total operating revenue of approximately 3.635 billion yuan, a slight increase of 0.13% year-on-year [2][7] - Operating profit reached about 440 million yuan, a substantial increase of 32.64% year-on-year [2][7] - Total profit was approximately 438 million yuan, up 30.73% year-on-year [2][7] - Net profit attributable to shareholders was around 288 million yuan, reflecting a year-on-year growth of 24.74% [2][7] - Basic earnings per share increased to 0.6414 yuan, a rise of 14.97% year-on-year [2][7] Asset and Equity Growth - As of the end of 2025, total assets were approximately 5.045 billion yuan, representing a growth of 10.71% from the beginning of the period [2][8] - Shareholder equity attributable to the company was about 3.030 billion yuan, a year-on-year increase of 23.06% [2][8] - The number of shares increased to approximately 492 million, up 16.09% from the previous year [2][8] Reasons for Performance Growth - The growth in performance was attributed to steady revenue growth from core industrial enterprises and improved profitability [3][9] - The acquisition of 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical and 68% of Hunan Qianjin Xieli Pharmaceutical contributed positively to the financial results starting from October and November 2025 [3][9] Market Value Management - The company emphasized its commitment to market value management, maintaining a high dividend payout ratio since its listing to reward shareholders [3][9] R&D and Innovation - R&D innovation is a key focus, with plans to increase investment and optimize product layout, currently having nine innovative drugs in development [5][11] - The company is implementing a digital transformation strategy across its operations to enhance efficiency and reduce costs, utilizing AI technology in various operational aspects [5][11] Channel Operations - Qianjin Pharmacy operates approximately 1,800 stores, with significant growth in sales of flu-related medications driven by market demand [6][12]

Core Insights - The strategic collaboration between Innovent Biologics and Eli Lilly, valued at over $8.8 billion, has garnered significant industry attention, marking their seventh partnership [1][19][18] - The agreement includes an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion, alongside a tiered sales revenue share for products outside Greater China [1][18] Group 1: Industry Trends - The surge in BD transactions and mergers in China's innovative pharmaceutical sector reflects the growing strength of Chinese drug companies, providing substantial economic benefits and multiple gains for multinational corporations (MNCs) [2][19] - In January 2026 alone, the potential total amount for BD transactions in China's innovative pharmaceuticals exceeded $33.2 billion, a 48.8% increase from $22.3 billion in the same month of 2025 [2][19] - The total amount for outbound licensing transactions in 2025 reached a historic high of $135.655 billion, indicating a strong trend for 2026 to potentially surpass this figure [2][19] Group 2: Shifts in Market Dynamics - The significance of Chinese innovative drug assets has shifted from being a means for local companies to generate cash to becoming coveted "treasures" that MNCs are eager to acquire [3][20] - The efficiency and cost advantages of Chinese innovative drugs are seen as critical for MNCs to fill pipeline gaps, while the R&D potential and patient base in China position MNCs as "ecosystem builders" rather than mere outsiders [3][20] Group 3: Innovations and Collaborations - The term "me-too" is no longer prevalent in discussions about Chinese innovation, as the focus has shifted to recognizing the importance of Chinese innovation in the global market [4][21] - At the JP2026 conference, leaders from major MNCs emphasized their commitment to the Chinese market and collaboration with local innovators, highlighting the strategic importance of Chinese innovation [5][22] - In 2025, 76 new drugs approved in China included 17 that received breakthrough therapy designation, with 12 being ranked first globally in their respective categories [5][22] Group 4: Commercialization and Development - The commercialization capabilities of Chinese pharmaceutical companies have evolved, with an increasing number of transactions involving "co-development" and "co-commercialization" agreements, expanding to include both the Chinese and global markets [11][28] - Innovent Biologics reported a total product revenue of approximately RMB 11.9 billion in 2025, reflecting a robust year-on-year growth of about 45%, driven by products like Ma Shidu and Tolebrutinib [12][29] - The partnership with Takeda, valued at $11.4 billion, represents one of the largest BD transactions in Chinese pharmaceutical history, involving collaboration on multiple drug candidates [13][30]

恒瑞医药公告要点解读 核心事项 恒瑞医药子公司苏州盛迪亚的注射用瑞康曲妥珠单抗新适应症上市申请获国家药监局受理，并纳入优先 审评程序。 国内尚无HER2靶向药获批用于HER2阳性结直肠癌，存在未满足临床需求 关键信息 同类产品2024年全球销售额合计约65.57亿美元 新适应症：治疗经奥沙利铂、氟尿嘧啶和伊立替康治疗失败的HER2阳性结直肠癌成人患者 该项目累计研发投入约17.73亿元（未经审计） 已获批适应症：2025年5月已获批用于HER2激活突变的晚期非小细胞肺癌 临床数据：基于III期临床试验，结果显示较标准治疗方案显著延长PFS，降低疾病进展或死亡风险 市场情况： ...

Core Viewpoint - Fangsheng Pharmaceutical emphasizes the importance of market value maintenance and has integrated it into the performance evaluation metrics of senior management [2] Group 1: Company Actions - The company is committed to improving its information disclosure mechanisms and enhancing communication with investors to foster a better understanding of its value [2] - Fangsheng Pharmaceutical adheres to a proactive and stable cash dividend policy to reward all shareholders [2] - The company focuses on the long-term sustainable development of its core business and aims to continuously strengthen operational management to drive stable growth and value creation [2]

ZG-002 片当前给药剂量、频率以及给药周期下安全性和耐受性良好，药代动力学特征清晰明确。ZG- 002 目前拟用于治疗中重度斑块状银屑病，有望成为新一代安全性更高、疗效更好的银屑病治疗药物， 并有潜力拓展到其他的自身免疫性疾病的临床应用。 公司通过控股子公司致根医药持续加大创新药研发投入。除ZG-002 外，ZG-001（抗抑郁药）已完成1 期临床试验，安全性优异，正在开展2a 期临床试验，公司与临床中心正在积极推进各项工作，预计将 于2026 年H1读出数据，验证疗效。 以湖南省天玑珍稀中药材发展有限公司为项目平台开展的ZY 系列濒危动物药材替代品各个项目的研究 工作稳步推进。其中，ZY022 项目预计年内完成IND 申请，进入1 期临床试验。 风险提示：行业竞争加剧风险、政策风险、研发不及预期风险、市场开拓不及预期风险等。 事件：公司发布公告，参股公司收到ZG-002 片Ⅰ期临床研究报告。ZG-002（抗自身免疫药，TYK2 变 构抑制剂）1 期临床试验已于近期完成，本次临床试验的目的主要是评估ZG-002 片在健康成年受试者 中的安全性和耐受性、药代动力学特征及食物影响等。 研究结果表明，ZG-00 ...

Group 1: Company Performance - Microchip Biotech forecasts a turnaround to profitability in 2025, with projected revenue of 910 million yuan, a year-on-year increase of 38.32% [1] - The net profit attributable to shareholders is expected to reach 53.46 million yuan, a significant improvement from a loss of 115 million yuan in the previous year, marking an increase of 168 million yuan [1] - Revenue growth is primarily driven by the commercialization of core products, with sales of Sigleptin sodium increasing approximately 123% due to its clinical value in "diabetes-liver management" and effective collaboration between self-operated and channel sales [1] - Sales of Sidabamine, despite facing price reductions and inventory adjustments, still achieved a year-on-year growth of 16% after being included in the national medical insurance catalog for a new indication of diffuse large B-cell lymphoma [1] Group 2: Strategic Developments - The company has made a breakthrough in business development by granting exclusive rights for Sidabamine to the Russian pharmaceutical company Nizhpharm for research, registration, and commercialization in 12 CIS and Central Asian countries [2] - Nizhpharm will pay an upfront fee of 10 million yuan and a milestone payment of 10 million yuan upon registration, along with a high double-digit percentage of net sales in the authorized regions [2] - Sidabamine is the world's first subtype-selective HDAC inhibitor, approved for multiple indications in China and Japan, and is currently undergoing Phase III clinical trials for additional indications [2] Group 3: Clinical Research Updates - Xioroni has updated data on pancreatic cancer, showing potential in treatment through both single-agent exploration in the U.S. and combination chemotherapy in China [3] - In a Phase II study for first-line treatment of pancreatic ductal adenocarcinoma, Xioroni combined with AG chemotherapy demonstrated a breakthrough efficacy potential, achieving an objective response rate (ORR) of 50% [3] - The median progression-free survival (mPFS) is reported at 9.1 months, with approximately half of the patients still on treatment after a median follow-up of 9.6 months [3] - Xioroni shows promising synergy with targeted drugs like RAS inhibitors in various mouse models, indicating enhanced tumor suppression effects when combined [3] - The U.S. Phase I dose-escalation trial for Xioroni is nearing completion, with the company actively advancing its overseas development and collaboration efforts [3]

Core Insights - Hong Kong's capital market showed remarkable performance in 2025, with total fundraising reaching $103 billion, a 164% year-on-year increase [1] - The initial public offering (IPO) fundraising amounted to $37.4 billion, up 231% year-on-year, while post-listing refinancing reached $66 billion, a 136% increase [1][3] - The secondary market was also active, with an average daily trading volume up 89.5% year-on-year [1] Group 1: Market Performance - Hong Kong regained its position as the global leader in IPO fundraising by the end of 2025, with 119 new listings raising a total of $37.4 billion, including two of the world's top five IPOs [3] - The total fundraising amount for the year was the highest since 2021, exceeding the total of the previous three years combined [3] - New stocks with fundraising of $100 million or more saw an average first-day price increase of 23.8% and a one-month average increase of 30.7%, marking the best performance in nearly 20 years [5] Group 2: Notable Transactions - The year recorded multiple landmark transactions, including 20 large deals over $1 billion, such as the largest placement in the global automotive sector and the second-largest convertible bond deal in the tech sector [5] Group 3: Market Optimization - Market activity significantly increased due to ongoing market optimizations, including the gradual implementation of an improved IPO pricing mechanism and public market regulations since August 2025 [7] Group 4: Investor Participation - The investor base in Hong Kong's primary and secondary markets has become increasingly diverse, including global institutional investors and retail investors from mainland China [9] - Institutional investors accounted for a significant portion of the top 20 most active cornerstone investors in Hong Kong's equity capital market [9] Group 5: International Listings - In 2025, the number of international companies listed in Hong Kong reached a five-year high, attracting issuers from the US, Southeast Asia, and the UAE [10] - Nearly one-fifth of the companies listed in Hong Kong were dual or multi-listed, including major Chinese companies expanding their international footprint [10] Group 6: Sector Diversity - Hong Kong maintained its status as a diversified fundraising center, ranking among the top globally in various industry fundraising scales [11] - In the industrial and new energy sectors, Hong Kong ranked first globally in IPO fundraising at $14.3 billion and second in equity capital market issuance at $24.7 billion [13] - The TMT sector saw a record issuance scale of $34.5 billion, with significant demand from investors, leading to oversubscription rates of 13 times for institutional investors and over 1,000 times for retail investors [13] Group 7: Traditional Industries - Traditional industries also performed well, with the largest consumer goods IPO and the two largest pure industrial companies choosing to list in Hong Kong [15] - The metals and mining sector led global IPO fundraising with $5.4 billion, while total equity financing reached $9.5 billion, the highest in nearly a decade [15] Group 8: Future Trends - The Hong Kong capital market started strong in 2026, with equity capital market issuance reaching $15.8 billion by January 30, six times the amount from the same period in 2025 [16] - Companies in the artificial intelligence sector made up a significant portion of IPO activities, contributing to a vibrant ecosystem for AI issuers [16] - Over 400 companies from diverse industries are currently waiting to list, including those in healthcare, materials, TMT, and industrial sectors [16]